Donate
Lifespan.io > Institutions > SIWA Therapeutics
×

Menu

Back

SIWA Therapeutics

https://siwatherapeutics.com/

Organization Description

SIWA Therapeutics are developing an immunotherapy approach to senescent cell accumulation and cancer. Their approach is really a typical monoclonal antibody product, the same sort of immunotherapy that’s used in a variety of cancer therapies. SIWA claims to have found a marker that’s on cancer cells and senescent cells because of the way the markers are produced, and therefore the monoclonal antibody can enable removal of those senescent or cancer cells.

Team

Lewis Gruber

SIWA Therapeutics

Related Topics

Cellular Senescence is one reason we age.
Why we Age: Cellular Senescence
As your body ages, more of your cells become senescent. Senescent cells do not divide or support the tissues of which they are part; instead, they emit potentially harmful chemical signals, collectively known as the senescence-associated secretory phenotype (SASP), which encourages nearby cells to enter the same senescent state. Their presence causes many problems: they degrade tissue function, increase chronic inflammation, and can even eventually raise the risk of cancer and other age-related ...
Read More

Related News

Interview with Lewis Gruber

Lewis Gruber – Senotherapeutics

At the recent Longevity Therapeutics Conference in San Francisco, we had the chance to interview Lewis Gruber of SIWA Therapeutics and discuss his company's senotherapeutic approach to cancer and senescent cells. He was accompanied by his wife, Misty, who is the CFO of SIWA. Many of our readers are familiar with CAR-T immunotherapy, which has...
Stay Connected
© 2021 - Lifespan Extension Advocacy Foundation - LIFESPAN2023
Privacy Policy
Terms Of Use
Sitemap

The opinions expressed in interviews or commentary in articles appearing on this site are those of the subject or subjects and do not necessarily reflect the views of LEAF/Lifespan.io, its directors, officers or employees.

Powered by MMD

Want the latest longevity news? Subscribe to our Newsletter!